All News
Fewer Psoriasis Patients Satisfied with Current Treatments
A new national survey in the United States of nearly 600 individuals with psoriasis, reveals that although patients have numerous treatment options, they have difficulty finding treatment plans that work. In addition, respondents reported a heavy emotional toll, with many feeling isolated and stigmatized due to the condition.
Read Article
RheumNow Week in Review – 12 August 2016
Watch Dr. Cush review 13 highlights from this week on RheumNow.
Read Article
No Added Lymphoma Risk with TNF Inhibitor Use
Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.
Read Article
Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis
The pathogenesis of Alzheimer's disease (AD) is unknown but some have speculated a role for inflammation.
Read Article
Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?
Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai
Read Article
Biosimilars are Bioequivalent to Original TNF Inhibitors
Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine. (Citation source: http://buff.ly/2arTd1q)
Read Article
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Read Article
Long-Term Safety of Adalimumab Reviewed
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
Read Article
Novel Rise of Combined Dermatology-Rheumatology Clinics
Rheumatology News has a novel online report about combined rheumatology-dermatology clinics. In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).
Read Article
RheumNow Week in Review – 22 July 2016
From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.
Read Article
FDA Panel Recommends Brodalumab Approval in Psoriasis
Valeant Pharmaceuticals International's experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.
Read Article
SAPHO Syndrome Revisted
SAPHO is an acronym that describes a constellation of findings (synovitis, acne, pustulosis, hyperostosis, and osteitis) that defines this rare syndrome.
Read Article
Will Patent Extensions Delay Biosimilar Arrivals?
In the last 6 months, the FDA Arthritis Advisory Committee has recommended three biosimilars (CT-P13, GP-2015, ABP-501) for approval, with one achieving FDA approval Inflectra/CT-P13) and the other two pending a probable approval in the months to come.
Read Article
ORBIT Study Shows Rituximab is Non-Inferior to TNF Inhibitors in Biologic Naive Patients
Porter and colleagues have reported that both rituximab (RTX) and tumour necrosis factor inhibitors (TNFi) are equally and highly effective in early, active, biologic-naive rheumatoid arthritis patients.
Read Article
Increaed GI Perforations with Tocilizumab Seen in German Registry Analysis
The issue of lower intestinal tract perforation (LIP) is no novelty to rheumatologists since the RA treatment paradigm shifted from use of NSAIDs (the most common cause of upper GI tract perforations) to steroids and non-steroidal DMARDs.
Read Article
RheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee
The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.
Read Article
FDA Approves Xiidra (Lifitegrast) for Dry Eyes
MedScape has reported that the US Food and Drug Administration (FDA) has approved lifitegrast ophthalmic solution (Xiidra, Shire) for the treatment of signs and symptoms of dry eye disease.
Read Article
FDA Arthritis Advisory Committee Recommends Approval of Adalimumab Biosimilar
The Food and Drug Administration’s Arthritis Advisory Committee yesterday recommended that Amgen biosimilar (ABP 501) to Humira (adalimumab) be approved for use in the United States.
Read Article
Vagal Stimulation Improves Cytokine Production and Rheumatoid Disease Activity
PNAS has published a study wherein an inducible “inflammatory reflex” delivered by vagus nerve stimulation was shown to inhibit the production of tumor necrosis factor (TNF), an inflammatory molecule that is a major therapeutic target in an animal model of rheumatoid arthritis (RA).
Read Article